Biohit GastroPanel® biomarkers validated as powerful predictors of gastric cancer risk in a multicenter study
Press release Biohit Oyj 9[th] April 2019 at 09.30 local time (EEST) Biohit GastroPanel[®] innovation is the unique non-invasive diagnostic tool for examination of i) dyspeptic patients for exclusion or diagnosis of Helicobacter pylori (Hp) infection and atrophic gastritis (AG), also disclosing the functional status of gastric acid output, as well asii) for screening of asymptomatic individuals for the risk of gastric cancer (GC)(1,2, www.gastropanel.com, www.biohithealthcare.com/additional-information). The outstanding performance of GastroPanel[®] test in diagnosing AG has been